Investor News

Acorda Therapeutics Completes $11.5 Million Private Financing


Hawthorne, NY March 4, 2004 - Acorda Therapeutics announced today that it has raised $11.5 million in a private financing comprising new and existing institutional investors.

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI), multiple sclerosis (MS) and related central nervous system disorders. The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 trials for MS. Acorda's technology platform also includes valrocemide, which is in clinical development for the treatment of epilepsy and bipolar disorder. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *